Drug Approval | February 26, 2022
Japan approves Keytruda plus Lenvima for two types of cancer
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Dr. Reddy’s to promote and distribute select Novartis products including the Voveran range, the Calcium range and Methergine in India
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
The Health ID will allow users to connect with different healthcare providers and enable a consent-based sharing of personal health records
2022 is going to be the year of opportunities and innovations from the medical industry in India
Subscribe To Our Newsletter & Stay Updated
